NeuExcell's Gene Therapy NXL-004 Shows Promising Results in First-in-Human Trial for Recurrent Malignant Glioma
核心洞察
NeuExcell Therapeutics (搜索) reported encouraging clinical results for NXL-004, the world's first in situ conversion gene therapy for malignant glioma (搜索), at ESMO Asia Congress 2025.
The first-in-human study of 11 patients with recurrent malignant glioma (搜索) showed median overall survival exceeding 12 months, significantly surpassing historical controls of 6-9 months.
NXL-004 demonstrated a favorable safety profile with no drug-related serious adverse events, and achieved one complete response with total tumor disappearance.
NeuExcell Therapeutics (搜索) announced encouraging clinical results for NXL-004, the world's first in situ conversion gene therapy for malignant glioma (搜索), at the ESMO Asia Congress 2025 in Singapore. The first-in-human study demonstrated promising efficacy and safety outcomes in patients with recurrent malignant glioma (搜索), a condition with an extremely poor prognosis and median survival under nine months.
Novel Therapeutic Approach
NXL-004 represents a first-in-class gene therapy that utilizes an adeno-associated virus (AAV) vector to deliver the neural transcription factor NeuroD1 (搜索) directly into glioma cells. This innovative approach reprograms tumor cells into non-dividing neurons or induces apoptosis, representing a novel therapeutic paradigm for treating malignant glioma (搜索).
Study Design and Patient Population
The first-in-human clinical study was jointly conducted by the Fourth Affiliated Hospital of Soochow University (搜索) and NeuExcell Therapeutics (搜索) to evaluate the safety and efficacy of intracranial NXL-004 administration. Eleven patients with recurrent malignant glioma (搜索) following surgery and chemoradiotherapy were enrolled in the trial.
Among the enrolled patients, ten received surgical tumor resection followed by intracavitary NXL-004 injection, while one patient received intratumoral NXL-004 injection following biopsy.
Safety and Efficacy Results
The study demonstrated a favorable safety profile for NXL-004, with no drug-related serious adverse events or dose-limiting toxicities observed across all treated patients.
Efficacy results showed significant improvement over historical controls. Following NXL-004 treatment, the estimated median overall survival exceeded 12 months, well above historical controls of 6-9 months for recurrent malignant glioma (搜索). The first patient enrolled in the study survived over 18 months post-surgery and treatment.
Tumor Response Outcomes
The trial achieved notable tumor response outcomes across different administration methods. The patient receiving intratumoral injection demonstrated a clear therapeutic effect, with significant regression of the target lesion showing shrinkage exceeding 90%.
Most remarkably, one patient who received tumor resection followed by intracavitary NXL-004 injection showed progressive tumor reduction on postoperative imaging, ultimately resulting in complete radiographic disappearance and achieving a complete response.
Clinical Significance
The results validate the feasibility and therapeutic potential of in situ conversion therapy for glioma treatment. This represents a significant advancement for patients with recurrent malignant glioma (搜索), who currently face limited treatment options and poor survival outcomes.
NeuExcell Therapeutics (搜索) has developed a core platform to reprogram internal glial cells directly into functional neurons via in situ conversion approach, targeting various neurological disorders including glioma, Alzheimer's (搜索), Parkinson's (搜索), and stroke (搜索).